Fortis Health. Q1 FY27 Earnings Call — Analysis (NSE: FORTIS)
Fortis Healthcare reports steady Q1FY27 with 17.5% revenue growth, maintains 25% consolidated EBITDA margin target by FY28 despite ESOP cost overlay.
Result quality: stable — Steady quarter. Management sentiment: optimistic.
The take
Q1FY27 Consolidated Revenue ₹2,545 Cr ( +17.5% YoY ) .
Results
Consolidated revenue ₹2,545 Cr (+17.5% YoY); operating EBITDA pre-ESOP ₹568 Cr (+15.8% YoY) with margin 22.3% (-30bps); hospital EBITDA margin 21.5% (-60bps); diagnostic EBITDA margin improved to 23.9% (+90bps).
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Consolidated Revenue | ₹2,545 Cr | +17.5% | yoy · Q1FY27 |
| Hospital Revenue | ₹2,187 Cr | +19% | yoy · Q1FY27 |
| Diagnostic Gross Revenue | ₹407 Cr | +10.2% | yoy · Q1FY27 |
| Consolidated Operating EBITDA (pre-ESOP) | ₹568 Cr | +15.8% | yoy · Q1FY27 |
| Consolidated Operating EBITDA Margin (pre-ESOP) | 22.3% | -30 bps | yoy · Q1FY27 |
| Hospital Operating EBITDA Margin | 21.5% | -60 bps | yoy · Q1FY27 |
| Diagnostic Operating EBITDA Margin | 23.9% | +90 bps | yoy · Q1FY27 |
| Consolidated PAT (before exceptional items) | ₹263 Cr | +4% | yoy · Q1FY27 |
| Net Debt | ₹2,233 Cr | point_in_time · Q1FY27 · as of Jun-26 | |
| Hospital ARPOB | ₹2.71 Cr | +2.6% | yoy · Q1FY27 · per annum |
Guidance
Management reiterated 25% consolidated EBITDA margin target post-ESOP by FY28, with FY27 hospital margin expansion of 150-200 bps ex-ESOP, and diagnostics revenue growth of 12-13% with EBITDA margin of 24-25%.
What management committed to
- We expect the growth momentum in revenue and improvement in operating EBITDA margin to continue going forward [for the Diagnostics business]. — double-digit revenue growth; margin improvement from 23.9%, ongoing
- We are expecting to operationalize another 400 beds in the remaining 3 quarters of the year. — 400 beds, FY27
- [Manesar hospital] by the month of November [2026], [radiation oncology equipment] should be installed. — installed, November 2026
- [Manesar and Noida hospitals], by the year-end [FY27], certainly be in the mid-teens as far as EBITDA [margin] is concerned, if not higher. — mid-teens percentage or higher, FY27 year-end
- We are very confident that we will be able to bring [Diagnostics business revenue growth] to the similar level [as industry peers, ~15%] within, say, next few quarters. — ~15%, next few quarters
- [Diagnostics business] revenue growth to be around 12%-13%, and EBITDA margin should be in the range of 24%-25% for the remaining time [of the year]. — revenue growth 12-13%; EBITDA margin 24-25%, FY27 remaining quarters
- We are still maintaining our [consolidated EBITDA margin] guidance [to reach 25% by FY28, including ESOP cost]. — 25%, FY28
Key themes
Margin recovery, brownfield ramp-up, and diagnostic turnaround
Operational commentary
- Added ~100 operational beds via brownfield expansion in Q1, primarily at Noida, Amritsar, Jalandhar; targeting further 400 beds in remaining FY27, with 200 beds at FMRI (Gurgaon) expected after occupancy certificate.
- Entered into O&M agreement for a 300-bed greenfield hospital in Cuttack, marking entry into Odisha without capital commitment, consistent with cluster-focused strategy.
- Board approved installation of proton therapy facility at flagship Gurgaon hospital, estimated capex of ~₹252 Cr.
- Installed Da Vinci Xi surgical robots at Faridabad and Fortis Escorts (Okhla), and Ortho robots at Jalandhar and Faridabad, bolstering advanced surgical capabilities.
- Diagnostics: achieved 1,000 whole exome sequencing tests on NovaSeq X platform, expanded network to 4,493 customer touch points, and processed ~10.5 million tests in Q1.
- Diagnostic mix improvement: B2C:B2B revenue mix improved to 53:47 (vs 51:49 YoY); preventive portfolio share reached 14% (vs 12%), specialised portfolio 35% (vs 34%).
- Oncology growth moderated to ~5% YoY due to government payor drug pricing (ECHS/CGHS) impact on chemotherapy; management sees future oncology growth at 10-12%, driven by radiation and surgical oncology.
Analyst Q&A
Q. On ESOP charge and margin trajectory: what is the annual charge and does the 25% EBITDA margin target by FY28 include ESOP cost?
Vivek Goyal confirmed ESOP charge ~₹40 Cr/quarter in FY27, gradually declining. The 25% margin target is aspirational after accounting for ESOP cost, with offsetting operational improvements.
Q. On diagnostics growth: top-line growth ~10% vs industry 15%, and whether this was related to brand transition.
Management acknowledged slower growth due to brand change stabilization, but highlighted B2C mix improvement and new leadership; guided for 12-13% revenue growth and 24-25% EBITDA margin going forward, citing a revival path.
Research and educational content only. Not investment advice.